A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung Cancer (SCLC).

Inclusion Criteria:

• Histologically or cytologically confirmed small cell lung cancer, without prior chemotherapy treatment
• Men and Women at least 18 years old
• Eastern Cooperative Oncology Group (ECOG) status 0-2

Exclusion Criteria:

• Significant cardiovascular disease
• Prior treatment of small cell lung cancer is not permitted, except for palliative radiation to a limited field excluding the chest (e.g. for painful metastasis).
• Symptomatic brain metastases
• Women pregnant or breastfeeding
• Women of childbearing potential (WOCBP) unwilling/unable to use acceptable method to avoid pregnancy
• Uncontrolled medical disorder or active infection
• Concurrent therapy with any other investigational product